Navigation Links
ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
Date:8/12/2013

BAUDETTE, Minn., Aug. 12, 2013 /PRNewswire/ -- ANI Pharmaceuticals (NASDAQ: ANIP) today announced that it has signed a binding letter of intent for the development of an oral soft gel prescription product with Sofgen Pharmaceuticals ("Sofgen.") The product, indicated for cardiovascular health, will be the subject of an Abbreviated New Drug Application ("ANDA") filing. Sofgen will be responsible for the development, manufacturing and regulatory submission of the product and ANI will be responsible for marketing and distribution in the United States.

Arthur S. Przybyl, ANI's President and CEO stated, "I am pleased to have entered into this collaboration with Sofgen for an oral soft gel drug.  In addition to our internal product development efforts, we will continue to pursue opportunities through external partnerships and acquisitions in order to leverage our core capabilities in manufacturing and marketing.  We are fortunate to have such a high quality partner in Sofgen."

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website www.anipharmaceuticals.com.

About Sofgen

Sofgen is a dynamic company established in Florida as a specialized developer and manufacturer of niche pharmaceutical products with high barriers to entry. Sofgen is part of the Procaps Group, which has a manufacturing network with facilities throughout North and South America, with a wealth of experience in soft capsules and related delivery technologies, servicing customers within the health sector in 50 different countries around the globe. For more information please visit our website www.sofgenpharma.com

Forward-Looking Statements

This news release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about ANI's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of ANI and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause ANI's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include the risk that ANI may in the future fail to meet NASDAQ listing requirements; general business and economic conditions; ANI's need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of ANI's licensees or sublicensees. More detailed information on these and additional factors that could affect ANI's actual results are described in ANI's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K, most recent quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this news release speak only as of the date made and are based on ANI's current beliefs and expectations. ANI undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information about ANI, please contact:
Arthur S. Przybyl
(218) 634-3608
arthur.przybyl@anipharmaceuticals.com


'/>"/>
SOURCE ANI Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Continuance
2. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
3. ANI Pharmaceuticals Reports Net Revenues of $6.2 million and adjusted non-GAAP EBITDA of $1.2 Million for the Second Quarter Ended June 30, 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
5. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
6. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
7. Isis Pharmaceuticals to Present at the Canaccord Genuity 33rd Annual Growth Conference
8. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
9. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
10. Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
11. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... UAE, May 23, 2016 Experts ... of Precision Medicine and the role of technology ...   The First International Conference of VPS-Penn Medicine ... distinguished patronage and presence of Sheikh Nahyan bin Mubarak Al ... in Precision Medicine, which helps provide personalized medicine and tailor-made ...
(Date:5/23/2016)... 23, 2016 The global  reprocessed ... billion by 2022, according to a new study by ... waste coupled with the lack of centralized support for ... drive the demand for reprocessed medical devices market. Additionally, ... to that of the original device is the high ...
(Date:5/22/2016)... DS Biopharma (DS) today ... compound DS102 in chronic obstructive pulmonary disease (COPD) ... patients. Recent DS preclinical data suggests ... and has bronchodilatory, anti-inflammatory and anti-fibrotic properties in ... will publish further detail on these findings later ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... Loma Linda University Health (LLUH) has officially broken ground on the hospital ... people looked on as the shovels hit the dirt at the community groundbreaking event ... the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of the ...
(Date:5/24/2016)... ... ... Boyd Industries, a leading supplier of dental chairs and cabinetry , ... pediatric dentistry , at AAPD 2016, the annual conference and trade show of the ... Unit keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery system ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that ... access to trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged ... concluded that the creative use of mobile digital devices can be an effective tool ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more people continue ... available and easily accessible. Whether someone chooses to cut gluten out of their life ... King Kullen Grocery stocks their shelves with many different gluten-free products all year round. ...
(Date:5/24/2016)... ... 24, 2016 , ... American Gene Technologies International, Inc ... its board of directors. Otterstatter is co-founder, president and CEO of Preventice, ... that lead to broad-based healthcare solutions. , “Jon knows how to create disruptive ...
Breaking Medicine News(10 mins):